Influenza treatment and/or characterization, human-adapted HA polypeptides; vaccines
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/145
A61K-039/12
출원번호
US-0239376
(2011-09-21)
등록번호
US-8802110
(2014-08-12)
발명자
/ 주소
Raman, Rahul
Koh, Xiaoying
Viswanathan, Karthik
Sasisekharan, Ram
Chandrasekaran, Aarthi
출원인 / 주소
Massachusetts Institute of Technology
대리인 / 주소
Choate, Hall & Stewart, LLP
인용정보
피인용 횟수 :
2인용 특허 :
32
초록
The present invention provides, among other things, methods, reagents, and systems for the treatment, detection, analysis, and/or characterization of influenza infections.
대표청구항▼
1. An engineered influenza hemagglutinin (HA) polypeptide that possesses at least 90% overall sequence identity with a reference HA polypeptide of SEQ ID NO: 1, which engineered HA polypeptide characterized in that its amino acid sequence includes: an amino acid residue (“Residue 137”) at a position
1. An engineered influenza hemagglutinin (HA) polypeptide that possesses at least 90% overall sequence identity with a reference HA polypeptide of SEQ ID NO: 1, which engineered HA polypeptide characterized in that its amino acid sequence includes: an amino acid residue (“Residue 137”) at a position corresponding to position 137 of SEQ ID NO:1 that is selected from the group consisting of arginine, lysine, glutamine, methionine and histidine; andan amino acid residue (“Residue 193”) at a position corresponding to position 193 of SEQ ID NO:1 that is selected from the group consisting of alanine, aspartic acid, glutamic acid, leucine, isoleucine, methionine, serine, threonine, cysteine, and valine; andan amino acid residue (“Residue 226”) at a position corresponding to position 226 of SEQ ID NO:1 that is selected from the group consisting of alanine, cysteine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan and valine; andan amino acid residue (“Residue 228”) at a position corresponding to position 228 of SEQ ID NO:1 that is selected from the group consisting of arginine, asparagine, aspartic acid, glutamic acid, glutamine, histidine, lysine, serine, glycine, threonine, and tyrosine. 2. The engineered HA polypeptide of claim 1, wherein the Residue 137 is selected from arginine, lysine, glutamine, and methionine. 3. The engineered HA polypeptide of claim 1, wherein the Residue 193 is selected from the group consisting of alanine, glutamic acid, threonine, cysteine, methionine, valine, and serine. 4. The engineered HA polypeptide of claim 1, wherein the Residue 226 is selected from the group consisting of leucine, isoleucine and valine. 5. The engineered HA polypeptide of claim 1, wherein the Residue 228 is selected from the group consisting of arginine, asparagine, serine, glycine, and threonine. 6. An engineered HA polypeptide characterized in that its amino acid sequence includes the Residue 137 is arginine; Residue 193 is threonine; Residue 226 is leucine; and Residue 228 is serine. 7. The engineered HA polypeptide of claim 1, wherein the HA polypeptide is an H2 polypeptide. 8. The engineered HA polypeptide of claim 1, characterized in that the HA polypeptide binds to umbrella-topology glycans with high affinity. 9. The engineered HA polypeptide of claim 8, wherein the HA polypeptide binds the umbrella topology glycans with an affinity comparable to that of a wild-type HA of the same subtype that is human transmissible. 10. The engineered HA polypeptide of claim 8, wherein the HA polypeptide binds the umbrella-topology glycans with an affinity that is at least 50% that of a wild-type HA of the same subtype that is human transmissible. 11. The engineered HA polypeptide of claim 8, wherein the HA polypeptide binds the umbrella-topology glycans with an affinity that is at least 70% that of a wild-type HA of the same subtype that is human transmissible. 12. The engineered HA polypeptide of claim 8, wherein the HA polypeptide binds the umbrella-topology glycans with an affinity that is at least 90% that of a wild-type HA of the same subtype that is human transmissible. 13. The engineered HA polypeptide of claim 8, wherein the HA polypeptide binds the umbrella-topology glycans with an affinity that is at least 100% that of a wild-type HA of the same subtype that is human transmissible. 14. The engineered HA polypeptide of claim 1, wherein the HA polypeptide binds to umbrella-topology glycans preferentially as compared with cone-topology glycans. 15. The engineered HA polypeptide of any claim 1, wherein the HA polypeptide binds to umbrella-topology glycans vs cone-topology glycans with a relative affinity of at least 2. 16. The engineered HA polypeptide of claim 1, wherein the HA polypeptide binds to umbrella-topology glycans vs cone-topology glycans with a relative affinity of at least 4. 17. The engineered HA polypeptide of claim 1, wherein the HA polypeptide binds to umbrella-topology glycans vs cone-topology glycans with a relative affinity of at least 10. 18. The engineered HA polypeptide of claim 1, wherein the HA polypeptide binds to umbrella-topology glycans vs cone-topology glycans with a relative affinity of at least 20. 19. The engineered HA polypeptide of claim 1, characterized in that the HA polypeptide binds to cone-topology glycans with low affinity. 20. The engineered HA polypeptide of claim 1, wherein the HA polypeptide binds to umbrella-topology glycans with a Kd′ of about 200 pM or less. 21. The engineered HA polypeptide of claim 19, wherein the HA polypeptide binds to umbrella-topology glycans with a Kd′ of about 100 pM or less. 22. The engineered HA polypeptide of claim 19, wherein the HA polypeptide binds to umbrella-topology glycans with a Kd′ of about 50 pM or less. 23. The engineered HA polypeptide of claim 19, wherein the HA polypeptide binds to umbrella-topology glycans with a Kd′ of about 20 pM or less. 24. The engineered HA polypeptide of claim 1, wherein the HA polypeptide binds to cone-topology glycans with a Kd′ of about 100 pM or more. 25. The engineered HA polypeptide of claim 23, wherein the HA polypeptide binds to cone-topology glycans with a Kd′ of about 200 pM or more. 26. The engineered HA polypeptide of claim 23, wherein the HA polypeptide binds to cone-topology glycans with a Kd′ of about 500 pM or more. 27. The engineered HA polypeptide of claim 23, wherein the HA polypeptide binds to cone-topology glycans with a Kd′ of about 1 nM or more. 28. The engineered HA polypeptide of claim 1, characterized in that the HA polypeptide binds to umbrella-topology glycans with high affinity and binds to cone-topology glycans with low affinity. 29. The engineered HA polypeptide of claim 28, wherein the HA polypeptide binds to umbrella-topology glycans with a Kd′ of about 200 pM or less and binds to cone-topology glycans with a Kd′ of about 200 pM or more. 30. A method of inducing an immune response by administering a composition comprising an engineered HA polypeptide of claim 1. 31. An immunogenic composition comprising the engineered HA polypeptide of claim 1. 32. The immunogenic composition of claim 31, wherein the immunogenic composition comprises a live attenuated virus. 33. The immunogenic composition of claim 31, wherein the immunogenic composition comprises virus-like particles. 34. The immunogenic composition of claim 31, wherein the immunogenic composition is a subunit immunogenic. 35. The immunogenic composition of claim 31, further comprising an adjuvant. 36. An engineered HA polypeptide wherein the improvement comprises the presence of an amino acid residue (“Residue 137”) at a position corresponding to position 137 of SEQ ID NO:1 that is selected from the group consisting of arginine, lysine, glutamine, methionine and histidine; andan amino acid residue (“Residue 193”) at a position corresponding to position 193 of SEQ ID NO:1 that is selected from the group consisting of alanine, aspartic acid, glutamic acid, leucine, isoleucine, methionine, serine, threonine, cysteine, and valine; andan amino acid residue (“Residue 226”) at a position corresponding to position 226 of SEQ ID NO:1 that is selected from the group consisting of alanine, cysteine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan and valine; andan amino acid residue (“Residue 228”) at a position corresponding to position 228 of SEQ ID NO:1 that is selected from the group consisting of arginine, asparagine, aspartic acid, glutamic acid, glutamine, histidine, lysine, serine, glycine, threonine, and tyrosine. 37. An engineered HA polypeptide wherein the improvement comprises the presence of an arginine at Residue 137, a threonine at Residue 193, a leucine at Residue 226 and a serine at Residue 228. 38. The engineered HA polypeptide of claim 1, wherein the polypeptide shows at least 91% overall sequence identity with a reference HA polypeptide of SEQ ID NO:1. 39. The engineered HA polypeptide of claim 1, wherein the polypeptide shows at least 92% overall sequence identity with a reference HA polypeptide of SEQ ID NO:1. 40. The engineered HA polypeptide of claim 1, wherein the polypeptide shows at least 93% overall sequence identity with a reference HA polypeptide of SEQ ID NO:1. 41. The engineered HA polypeptide of claim 1, wherein the polypeptide shows at least 94% overall sequence identity with a reference HA polypeptide of SEQ ID NO:1. 42. The engineered HA polypeptide of claim 1, wherein the polypeptide shows at least 95% overall sequence identity with a reference HA polypeptide of SEQ ID NO:1. 43. The engineered HA polypeptide of claim 1, wherein the polypeptide shows at least 96% overall sequence identity with a reference HA polypeptide of SEQ ID NO:1. 44. The engineered HA polypeptide of claim 1, wherein the polypeptide shows at least 97% overall sequence identity with a reference HA polypeptide of SEQ ID NO:1. 45. The engineered HA polypeptide of claim 1, wherein the polypeptide shows at least 98% overall sequence identity with a reference HA polypeptide of SEQ ID NO:1. 46. The engineered HA polypeptide of claim 1, wherein the polypeptide shows at least 99% overall sequence identity with a reference HA polypeptide of SEQ ID NO:1.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (32)
Peterson Steven F. (West Linn OR), Ampule filling device.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.